Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 22;12(2):402–415. doi: 10.1158/2159-8290.CD-21-0697

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 4. Time on treatment by best response in patients with CCA who received (A) futibatinib 20 mg once daily or (B) futibatinib 16 mg once daily. Time on treatment (color coded by best overall response) of each patient with CCA who received futibatinib at (A) 20 mg once daily (n = 64) or (B) 16 mg once daily (n = 19). NE, not evaluable; PD, progressive disease; QD, once daily. — Time on treatment by best response in patients with CCA who received (A) futibatinib 20 mg once daily or (B) futibatinib 16 mg once daily. Time on treatment (color coded by best overall response) of each patient with CCA who received futibatinib at (A) 20 mg once daily (n = 64) or (B) 16 mg once daily (n = 19). NE, not evaluable; PD, progressive disease; QD, once daily.